Sign In
Buy BCYP
$8.44
+0 (+0%)
At Close: May 12, 2022
Big Cypress Acquisition (OTCMKTS:BCYP) Shares Pass Below Two Hundred Day Moving Average – What’s Next?
03:25am, Friday, 17'th Apr 2026
Shares of Big Cypress Acquisition Corp. (OTCMKTS:BCYP - Get Free Report) passed below its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $8.44 and traded
Big Cypress Acquisition (OTCMKTS:BCYP) Shares Pass Below 200-Day Moving Average – Here’s What Happened
04:09am, Wednesday, 01'st Apr 2026
Big Cypress Acquisition Corp. (OTCMKTS:BCYP - Get Free Report)'s stock price crossed below its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $8.44 and tra
Analyzing Inhibikase Therapeutics (NYSE:IKT) and Big Cypress Acquisition (OTCMKTS:BCYP)
02:09am, Wednesday, 18'th Feb 2026
Inhibikase Therapeutics (NYSE: IKT - Get Free Report) and Big Cypress Acquisition (OTCMKTS:BCYP - Get Free Report) are both small-cap medical companies, but which is the superior business? We will con
Big Cypress Acquisition (OTCMKTS:BCYP) Stock Price Crosses Above 50-Day Moving Average – Here’s Why
03:30am, Wednesday, 11'th Feb 2026
Big Cypress Acquisition Corp. (OTCMKTS:BCYP - Get Free Report)'s stock price passed above its 50 day moving average during trading on Tuesday. The stock has a 50 day moving average of $8.44 and traded
Comparing Inhibikase Therapeutics (NYSE:IKT) and Big Cypress Acquisition (OTCMKTS:BCYP)
01:44am, Friday, 06'th Feb 2026
Big Cypress Acquisition (OTCMKTS:BCYP - Get Free Report) and Inhibikase Therapeutics (NYSE: IKT - Get Free Report) are both small-cap medical companies, but which is the better investment? We will con
Big Cypress Acquisition (OTCMKTS:BCYP) Shares Cross Below Fifty Day Moving Average – Here’s Why
04:58am, Tuesday, 27'th Jan 2026
Big Cypress Acquisition Corp. (OTCMKTS:BCYP - Get Free Report) passed below its 50-day moving average during trading on Monday. The stock has a 50-day moving average of $8.44 and traded as low as $8.2
SIOUX FALLS, S.D.--(BUSINESS WIRE)---- $BCYP #ACTG--SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-
Big Cypress Acquisition Corp Announces Special Meeting of Stockholders to Approve Business Combination with SAB Biotherapeutics
07:00am, Thursday, 23'rd Sep 2021
MIAMI, Sept. 23, 2021 /PRNewswire/ -- Big Cypress Acquisition Corp (NASDAQ: BCYP), (Big Cypress) a publicly-traded special purpose acquisition company focused on innovative biopharmaceutical firms, to
SIOUX FALLS, S.D.--(BUSINESS WIRE)---- $BCYP #BARDA--SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high
SAB Biotherapeutics Announces Completion of Enrollment in Phase 2a Challenge Trial of SAB-176 for the Treatment of Seasonal Influenza
07:00am, Wednesday, 15'th Sep 2021
SIOUX FALLS, S.D.--(BUSINESS WIRE)---- $BCYP #BCYP--SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-
SAB Biotherapeutics Announces Nonclinical Data Demonstrating SAB-185 Potently Neutralizes Delta and Lambda SARS-CoV-2 Variants
07:00am, Wednesday, 11'th Aug 2021
SIOUX FALLS, S.D.--(BUSINESS WIRE)---- $BCYP #BCYP--SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-
SAB Biotherapeutics to Present at the Ladenburg Thalmann Annual Healthcare Conference 2021
07:00am, Friday, 09'th Jul 2021
SIOUX FALLS, S.D.--(BUSINESS WIRE)--SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-h
SAB Biotherapeutics Announces Publication of Preclinical Data Demonstrating SAB-185 Effectively Neutralizes SARS-CoV-2 Variants
07:06am, Thursday, 08'th Jul 2021
SIOUX FALLS, S.D.--(BUSINESS WIRE)---- $BCYP #COVID19--SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, hi
MIAMI, July 7, 2021 /PRNewswire/ -- Big Cypress Acquisition Corp. (NASDAQ: BCYP), (Big Cypress) a blank check company focused on innovative biopharmaceutical firms, today announced the confidential s
SIOUX FALLS, S.D. & MIAMI--(BUSINESS WIRE)--SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces targeted, high potency, fully-human
